Cagrilintide Research in 2026: Amylin Signalling, CagriSema & REIMAGINE

THISTLE BIOLABS JOURNAL  •  2026 RESEARCH UPDATE

Cagrilintide sits in a different signalling family from GLP-1. That is exactly why amylin research has become so interesting: it creates another pathway to study alongside incretin biology.

What is amylin signalling?

Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells. Its biology is distinct from GLP-1, even though both pathways are studied in metabolic regulation. Amylin-receptor signalling has therefore become an important research area in its own right.

Cagrilintide is a long-acting amylin analogue developed to investigate this pathway over an extended exposure period.

Why combine amylin and GLP-1?

CagriSema combines cagrilintide with semaglutide. From a research perspective, the combination is interesting because it brings two distinct signalling systems together rather than simply increasing activity at one receptor family.

That creates useful questions around additive or complementary effects, pathway interactions and whether the combined response differs from either component alone.

What REIMAGINE 2 added in 2026

REIMAGINE 2 was published in The Lancet Diabetes & Endocrinology in 2026. It was a double-blind, randomised Phase 3 study comparing cagrilintide-semaglutide with semaglutide, cagrilintide and placebo in people with type 2 diabetes.

The study adds to a growing late-stage evidence base around combined amylin and GLP-1 receptor strategies. It also provides a much larger clinical context than earlier mechanistic or small proof-of-concept work.

Why the mechanism still matters

Large clinical trials can show what happened in a defined population, but they do not replace mechanistic research. Researchers still need to understand receptor pharmacology, exposure-response relationships, pathway selectivity and how each component contributes to the combined effect.

This is particularly important for multi-pathway strategies, where the behaviour of the combination may not be obvious from studying either component in isolation.

What to watch next

• Additional peer-reviewed REIMAGINE publications.
• Comparative work separating the cagrilintide and GLP-1 components.
• Mechanistic studies of amylin-receptor signalling.
• Regulatory developments around fixed-dose combination products.
• How trial findings translate into broader questions about multi-pathway metabolic research.

Amylin research is useful precisely because it broadens the metabolic peptide conversation beyond GLP-1 alone.

Source: The 2026 REIMAGINE 2 Phase 3 publication.